(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 October 2020 (22.10.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/212297 A1

(51) International Patent Classification:
A61K 9/48 (2006.01) *A61K 35/741* (2015.01)
A61K 35/74 (2015.01)

(21) International Application Number:
PCT/EP2020/060370

(22) International Filing Date:
14 April 2020 (14.04.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
19382287.1 15 April 2019 (15.04.2019) EP

(71) Applicants: **INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER (IDIBAPS)** [ES/ES]; C. Rosselló, 149-153, 08036 BARCELONA (ES). **FUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA** [ES/ES]; C. Rosselló, 149-153, 08036 BARCELONA (ES). **HOSPITAL CLÍNIC DE BARCELONA** [ES/ES]; C. Villarroel 170, 08036 BARCELONA (ES). **UNIVERSITAT DE BARCELONA** [ES/ES]; Centre de Patents de la UB, Baldiri Reixac 4 - Torre D, 08028 BARCELONA (ES).

(72) Inventors: **SUÑÉ NEGRE, Josep M.**; Centre de Patents de la UB, Baldiri Reixac 4 - Torre D, 08028 BARCELONA (ES). **SORIANO VILADOMIU, Alex**; C. Villarroel 170, 08036 BARCELONA (ES). **AIRA GOMEZ, Andrea**; C. Rosselló, 149-153, 08036 BARCELONA (ES). **FEHER, Csaba**; C. Villarroel 170, 08036 BARCELONA (ES).

(74) Agent: **ZBM PATENTS - ZEA, BARLOCCI & MARKVARDSEN**; Rambla de Catalunya, 123, 08008 BARCELONA (ES).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

WO 2020/212297 A1

(54) Title: LONG-TERM STABLE LIVE FECAL MICROBIOTA COMPOSITION

(57) Abstract: The present invention provides a solid oral pharmaceutical composition comprising a pharmaceutically effective amount of living microorganisms and one or more pharmaceutically acceptable water absorbing excipient(s), wherein the composition has a water content, determined according to European Pharmacopoeia 9.4, section 2.5.12., from 0.5 to 30% with respect the total weight of the composition. The invention also provides processes for its preparation as well as it use in therapy. The live-cell based composition of the invention is stable at mild conditions.